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Hormone receptor status is typically performed in formalin-fixed, paraffin-embedded tissue sections by immunohistochemistry (IHC). Only nuclear staining is considered positive. There are many tissue and technical variables that can affect test results, and the assays must be validated to ensure their accuracy. External proficiency testing surveys for estrogen receptor (ER) and progesterone receptor (PgR) for breast cancer are available from the CAP and other organizations and may be useful tools to help ensure that assays perform as expected. To avoid false-negative results, appropriate internal and external controls should be positive. In the endometrium, benign endometrial glands, endometrial stroma, or myometrium can serve as internal control tissue. If internal controls are not present, consider repeating the test on another specimen (if available). Reasons for false-negative results include the following:
 Exposure of tumor cells to heat (eg, carcinomas transected by using cautery during surgery)  Prolonged cold ischemic time, which may result in antigenic degradation. One hour or less is preferable  Under-or overfixation; fixation for at least 6 hours in buffered formalin is recommended, and prolonged fixation can also diminish immunoreactivity  Type of fixative: ER is degraded in acidic fixatives such as Bouin's and B-5; formalin should be buffered to ensure pH range between 7.0 and 7.4  Decalcification, which may result in loss of immunoreactivity  Non-optimized antigen retrieval or use of old (weeks) tissue sections  Type of antibody  Dark hematoxylin counterstain obscuring faintly positive diaminobenzidine (DAB) staining False-positive results occur less frequently. Rare reasons would be the use of an impure antibody that cross-reacts with another antigen or misinterpretation of entrapped normal or hyperplastic cells as invasive carcinoma. False-positive tests can also be generated by image analysis devices that mistakenly count overstained nuclei.
Reporting Guidelines
There are currently no outcome-driven consensus opinions that have been developed for the reporting of the results of immunohistochemical assays for ER and PgR for endometrial cancer. In absence of robust data, the CAP recommends using a similar reporting format that is used for reporting the results of immunohistochemical assays for ER and PgR for breast cancer (Table 1) . 2 As there is a wide range of receptor levels in individual cancers, a uniform reporting scheme using the proportion of positive cells as well as the intensity of immunoreactivity is recommended:
• Number of positive cells: The number of positive cells can be reported as a percentage or within discrete categories. • Intensity: Refers to degree of nuclear positivity (ie, pale to dark). The intensity can be affected by the amount of protein present, as well as the antibody used and the antigen retrieval system. In most cancers, there is heterogeneous immunoreactivity with pale to darkly positive cells present.
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Reporting Results of Estrogen Receptor (ER) and Progesterone Receptor (PgR) Testing

Result Criteria Comments Positive
Immunoreactive tumor cells present (≥1%)
The percentage of immunoreactive cells may be determined by visual estimation or quantitation. Quantitation should be provided by reporting the percentage of positive cells in the entire section. If there is significant regional variation, that too should be reported. 
B. HER2 (ERBB2) Testing
There are currently no guidelines that have been developed for the reporting of the results of HER2 testing on endometrial cancer. In the absence of such data, the CAP recommends using a similar reporting format that is used for reporting the results of HER2 testing for breast cancer. 1 If DNA MMR IHC has not been performed, this testing should be recommended for any case that shows an MSI-H phenotype, because this information will help identify the gene that is most likely to have a germline (or somatic) mutation.
HER2 (ERBB2) Testing by Immunohistochemistry
F. p53 Expression
The distinction between endometrioid and serous type endometrial carcinomas is typically based on morphologic evaluation. Analysis for p53 gene mutations can occasionally be useful for diagnostically challenging tumors which are not morphologically distinguishable between endometrioid and serous phenotypes. The vast majority of serous type endometrial carcinomas exhibit mutations in p53. While most low-grade endometrioid endometrial tumors are not associated with p53 mutations, a significant subset of high-grade endometrioid tumors are; thus, any ancillary testing for the presence of a p53 mutation should be performed with an awareness of the limitations of the result with respect to providing a conclusive answer as to exact tumor type. 1-2 On occasion, p53 testing may be requested for treatment purposes.
Extent of p53 specific nuclear immunostaining can be used to assess p53 gene integrity in endometrial carcinoma. Normal endometrial glands with an intact p53 gene express the protein at low levels, reaching a threshold of immunohistochemical detection (positive staining) in only a small percentage of cells. Generally this is 1% to 5% of nuclei, but may increase under conditions of cellular damage or repair. Two different staining patterns are each considered diagnostic of abnormalities of the p53 gene itself. Most common are mutations resulting in a qualitatively abnormal p53 protein that stabilizes the p53 complex, resulting in intense nuclear staining in >90% of affected cells. In most cases that harbor mutations in p53 that are associated with overexpression, intense nuclear staining is present in over 90% of affected cells. Second is genomic damage causing loss of expression, with complete absence of protein in all affected cells. The latter null phenotype must be distinguished from a failed stain. Low levels of expression within internal control tissues (stroma, or nonmalignant epithelium) can be used for this purpose. It should be noted that p53 expression is significantly affected by non-optimized antigen retrieval or use of archival (weeks) tissue sections.
